FLX Bio Announces Poster Presentations at the American Society of Hematology Conference on FLX925, a Small Molecule FLT3/CDK4/6 Inhibitor

South San Francisco, California, December 1, 2016

FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology agents and molecularly targeted therapies, announced today that it will present two abstracts on preclinical data for FLX925, a small molecule FLT3/CDK4/6 inhibitor, at the American Society of Hematology Conference to be held Dec 3-6, 2016 in San Diego, CA.

Currently in Phase I clinical trials, FLX925 is an oral drug targeting mutant forms of the FLT3 kinase, a critical oncogenic protein that promotes cancer cell growth in many patients with acute myeloid leukemia (AML) and other cancers. FLX925 simultaneously targets a second pathway involved in AML cell growth, known as CDK4/6. FLX925’s dual-inhibitor action may be more effective in treating FLT3-mutated AML than other FLT3 inhibitors, resulting in greater clinical benefit.

Abstract Information

Title: FLX925 Is a Rationally Designed FLT3, CDK4/6 Inhibitor with a Desirable Resistance Profile
Number: 2323
Presenter: Jordan Fridman
Program: Oral and Poster Abstracts
Session: 802. Chemical Biology and Experimental Therapeutics: Poster I
Time and Location:
Saturday, December 3, 2016: 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center)

Title: A Machine-Learning Analysis Suggests That FLX925, a FLT3/CDK4/6 Kinase Inhibitor, Is Potent Against FLT3-Wild Type Tumors Via Its CDK4/6 Activity
Result Type: Paper
Number: 3520
Presenter: Gene Cutler
Program: Oral and Poster Abstracts
Session: 802. Chemical Biology and Experimental Therapeutics: Poster II
Time and Location:
Sunday, December 4, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

About FLX Bio

Founded in 2015 following the acquisition of its predecessor company, Flexus Biosciences, Inc., by Bristol-Myers Squibb, FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents. The company leverages its unique insights in cancer biology and the immune system to discover and develop novel oral medicines that activate immune responses to eliminate cancer cells.

Located in South San Francisco, Calif., and funded by leading investors, including Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG) and Celgene, FLX Bio has assembled a leadership team and advisory group with a proven track record of success and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.

Contact: inquiries@flxbio.com

Back